EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox

Zinger Key Points
  • Treatment with a DNA tolerizing 'inverse vaccine' delayed the onset of paralysis.
  • Multiple Sclerosis protein fragment is also found in monkeypox virus supporting a potential role in the vaccine development.
EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox

Pasithea Therapeutics Corp KTTA has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS).

PAS002 vaccine construct encodes GlialCAM, a molecule found in the brain's white matter that is attacked in MS. 

GlialCAM shares a component of its protein structure that mimics an identical component of the Epstein Barr Virus (EBV) Nuclear Antigen-1, which plays a critical role in triggering MS. 

What Happened: The data showed that the engineered DNA plasmids provide a high level of efficacy in reducing multiple sclerosis severity and incidence of relapse.

A statistically significant reduction in disease and relapse severity was observed compared to the vehicle.

Also Read: EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition.

The treatment with a DNA vaccine prevented disease in approximately 50% of the mice compared to the vehicle.

How Does It Work: In three groups, a proprietary DNA cassette was engineered to encode GlialCAM and injected to block acute disease and its relapse potentially. 

These DNA molecules were designed to protect against paralytic disease by tolerizing the immune system so it would not attack myelin (the insulating layer around the nerves) in the brain and spinal cord. 

What's Next: The company has filed a provisional patent application.

Pasithea plans to present data from this study, including histology data and plasma inflammatory markers, in future major international conferences and submit full data for peer-review publication.

GlialCAM protein is also found in the pox viruses, including monkeypox.  

The company says that the technology may be helpful as a treatment for brain inflammation caused by certain viral infections.

Price Action: KTTA shares closed 0.87% higher at $1.17 on Wednesday.

Posted In: Monkeypoxmultiple sclerosisBiotechNewsPenny StocksHealth CareMarket-Moving ExclusivesExclusivesGeneral

This Company Reports Its Consumer Therapeutics Could Be A Game Changer For People With Skin Problems

This Company Reports Its Consumer Therapeutics Could Be A Game Changer For People With Skin Problems

From allergies and insect bites to sunburns and irritations, the human skin can succumb to several conditions, including acne, psoriasis, blisters, hives, actinic keratosis, rosacea, and carbuncle.

Skin diseases are more prevalent than many think; they currently make up 1.79% of the global disease burden.

Zooming in on the U.S., the American Academy of Dermatology (AAD) reports that 84.5 million Americans — 1 in 4 — are impacted by skin diseases.

In addition to the debilitating physical and emotional impact, skin diseases can have on people, they can also be a financial strain. Skin diseases cost the U.S. healthcare system $75 billion in medical, preventative and prescription, and nonprescription drug costs.

For every three Americans with skin disease, the AAD reports that a dermatologist saw only one.

To make matters worse, the dermatology association also observed that acne has become a significant problem among teenagers  — more than 85% of young people suffer from at least one form of acne.

Demand for effective therapies is growing as cases continue to soar. Luckily, a large number of drugs from companies like AbbVie Inc. ABBV, GSK plc GSK, Eli Lilly and Co. LLY, and Viatris Inc. VTRS have been approved to treat various dermatologic conditions.

These drugs are contributing to the growth of the global dermatology treatment market. The market size was $36.82 billion in 2019 and is projected to reach $63.99 billion by 2027, exhibiting a compound annual growth rate (CAGR) of 12.9% during the forecast period.

For a company like Jupiter Wellness Inc. JUPW, which is ramping up research, development, and trial of new therapies, the market's growth, and need could present opportunities.

The company’s clinical pipeline of prescription skin-care therapeutics addresses health conditions such as eczema, burns, herpes, cold sores, and skin cancer.

Founded in 2018, Jupiter Wellness is engaged in early-stage manufacturing, distribution, and marketing of consumer products.

A Look At Jupiter Wellness’s Consumer Products 

The Jupiter, Florida-based company’s clinical pipeline includes JW-100, a novel topical formulation containing CBD and aspartame for treating eczema, dermatitis, and actinic keratosis.

Also in the pipeline is JW-300, a prescription product for treating burns, and JW-400, a nonprescription lotion/lip balm for treating symptoms of cold sores.

Eczema (JW-100):  Topical treatment for atopic dermatitis (eczema)

According to Jupiter Wellness, studies showed that JW-100 cleared or reduced eczema symptoms after two weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs.

A Phase 3, double-blind, placebo-controlled multicenter trial is underway to evaluate the superiority of JW-100 to Eucrisa a Food and Drug Administration (FDA)-approved topical drug) in mild to moderate eczema.

Female sexual wellness (RJ-101):  Topical treatment for female libido loss

The company’s studies showed that RJ-100 increased nipple erection, sensitivity, and genital lubrication in clinical trials conducted on normal patients and those with nipple neuropathy.

Jupiter Wellness hopes to launch RJ-101 in 2023 and anticipates it will be sold as an over-the-counter (OTC) treatment for female sexual dysfunction and as a consumer product for general sexual wellness and pleasure.

Hair Loss (Minoxidil Booster): Topical treatment designed to improve Minoxidil efficacy

The company reports minoxidil is the only FDA-approved topical drug for treating common hair loss (androgenetic alopecia). 

The company says clinical studies of Minoxidil Booster have shown it increases the enzymes needed for minoxidil to work, sulfotransferase enzymes, by up to seven times over a two-week period.

Minoxidil Booster has been licensed to Taisho Pharmaceutical Holdings, a $2.6 billion company and Japan’s leading seller of minoxidil products. It expects to launch the product commercially in 2023.

It has also been licensed to India-based Cosmofix Technology and Sanpellegrino Cosmetics and is expected to be launched soon.

Psoriasis and vitiligo (Photocil): Topical treatment for psoriasis and vitiligo

 Jupiter Wellness says Photocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and allowing the passage of therapeutic ultraviolet (UV) radiation.

It is anticipated that Photocil will be available online in the U.S. in the fourth quarter of 2022 as an FDA-approved over-the-counter product under a United States Pharmacopeia (USP) monograph for psoriasis and vitiligo.

The company reports that clinical trial results showed that Photocil cream acts as a barrier to nontherapeutic radiation from the sun when skin is exposed to direct daylight. 

Burns (JW-300): Topical treatment of first-degree burns and sun exposure

Jupiter Wellness reports that JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation.

JW-300 is being evaluated for sale as an after-sun consumer product to complement the company’s NoStingz sunscreen — topical protection from jellyfish, sea lice, and ultraviolet A (UVA)/ultraviolet B (UVB) rays — and legacy sun care product lines.

Cold sores (JW-400): Topical treatment for herpes labialis (cold sores)

Jupiter Wellness revealed that phase 1, a double-blind placebo-controlled investigational study in Europe and Asia with FDA-similar protocols initiated in preparation for FDA Investigational New Drug (IND) filing.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured photo from Shutterstock

Posted In: Jupiter WellnessPartner ContentBiotechPenny StocksGeneral